Atara Biotherapeutics (ATRA) 10-K2022 FY Annual report

Filed: 8 Feb 23, 4:54pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ACA, adult, aforementioned, ARA, ARC, ATOM, attrition, bearing, began, Beth, biomanufacturing, bioreactor, Biotech, Bribery, Briumvi, burn, Carlsbad, Carol, Carykti, CECL, Chair, Chancery, ciltacabtagene, Commerce, compensatory, conference, Connecticut, CTD, CTR, culminated, dataset, DGCL, distributor, Dobmeier, doctrine, doubt, doubtful, Ebvallo, EC, embedded, English, erasure, Eric, fashion, fiduciary, forfeited, forgoing, Fust, Gallagher, GMP, Grazia, HCR, HCRx, Heiden, heighted, hereof, IA, IDSMC, imputed, inapplicable, inflationary, Inline, invasion, IRA, Koppikar, leader, leaner, led, Legend, leukocyte, Linkbase, lump, lymphoma, Maria, Master, Matthew, Molag, Moonshot, MRI, MSA, necessity, novation, oComparing, oConfirmed, oEvaluated, older, oPerformed, oPerforming, oRead, oTesting, outlicensed, Page, partnership, Pascal, penalize, PF, Pharm, poverty, Pub, reagent, reclassified, recombinant, rental, resonance, Retraining, revert, reverted, Roncarolo, ROU, Russian, SAFC, Schema, Seidenberg, signature, specialty, St, stead, strict, style, Taxonomy, thereunto, therewith, thing, toa, Touchon, transatlantic, true, TSA, Ukraine, undersigned, understood, uninterrupted, Utah, Utpal, variance, Virginia, wholesale, William, Worker, XBRL

Removed: acceleration, acute, AML, Blvd, building, circumvent, commissioning, confirm, constructing, description, EAP, Gateway, grow, hematologic, incentivize, launching, leukemia, lisocabtagene, myeloid, NaN, owner, participant, plant, remanded, replacing, subpopulation, supplement, upheld

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ATRA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in registration statements No. 333-199508, No. 333-204076, No. 333-209961, No. 333-214431, No. 333-219763, No. 333-223254, No. 333-229861, No. 333-236704, No. 333-249976, No. 333-253734, No. 333-259882, No. 333-263109 and No. 333-266288 on Form S-8 of our reports dated February 8, 2023, relating to the consolidated financial statements of Atara Biotherapeutics, Inc. and subsidiaries (the “Company”) and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2022.

/s/ DELOITTE & TOUCHE LLP

San Francisco, California

February 8, 2023